Capricor Therapeutics Inc (CAPR)

[staccani]

https://clinicaltrials.gov/ct2/show/record/NCT03406780 study is active but not recrruting. FDAQ requested a type 2 meeting to decide if this trial could serve as registration trial. I guees they are meeting FDA soon and in the meantime suspended enrolment. Could you imagine what would happen to stock price if FDA decides this is enough for a BLA? Worldwide there is a potential market of 100,000 not ambuling people, at 600,000 pa. each, even a 10% market penetration would mean $6B revenue and a market cap anywhere between $30 and $50B. The company has $13M market cap now!